KA/EN
Register
Medicines reference
Search
Search
Product

Dexamethasone-AJIO

Favourites

Dexamethasone · Ajio Pharmaceuticals

1 form: solution. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
4 mg/ml, Solution No label dose in the reference yet - Georgia Yes, human
In force until 24 Aug 2028
Human (Ministry of Health, RAMA)
In the register: დექსამეტაზონ-აჯიო 4 მგ/მლ, 1 მლ ამპულა
№ რ-038922
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Dexamethasone-AJIO 4 mg/ml, Solution

1 ml ampoule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care
6.1/10
Situational / acceptable
vetman assessment

Dexamethasone-AJIO

4 mg/ml, 1 ml ampoule, human medicine
Assessed clinical scopeDog · Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care · IV,IM
Care settingVeterinary clinic or hospital use after diagnosis and contraindication review, with exact small-volume measurement, route-specific administration, infection management and clinical/metabolic monitoring
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-038922 · Verified on 16 Oct 2026 Off-label use

A useful, precisely measurable clinic formulation when a diagnosed condition genuinely warrants parenteral dexamethasone and oral treatment is unsuitable. Its value is diagnosis-dependent, veterinary use of the exact human ampoule is off-label, and routine use for uncomplicated allergy or anaphylaxis is not supported; screen contraindications and avoid NSAID overlap.

Regulatory and scientific credibility5.5/10

The exact 4 mg/ml human ampoule has a sourced current Georgian registration and identifiable strength, route and manufacturer, but no current exact EU/EEA, GB or US registration was found. Animal use is off-label and formulation-specific veterinary evidence is absent.

Clinical efficacy6.0/10

Dexamethasone is a potent, established veterinary anti-inflammatory glucocorticoid and short systemic courses can be useful for selected severe inflammatory or immune-mediated disease. Benefit varies sharply by diagnosis: current RECOVER guidance recommends against routine glucocorticoids for uncomplicated allergy and anaphylaxis, and evidence does not validate every broad historical use or this exact human ampoule.

Safety and tolerability5.5/10

A single selected dose is usually tolerated, but dexamethasone is long acting and highly potent. It can worsen infection, hyperglycaemia, gastrointestinal ulceration, fluid/electrolyte disturbance, delayed healing and HPA suppression; pregnancy, diabetes, hyperadrenocorticism and major cardiac, renal, ocular or ulcer disease materially change the benefit-risk.

Clinical practicality8.0/10

The sterile 4 mg/ml, 1 ml ampoule supports rapid IV or IM clinic administration and avoids a prolonged home regimen. At the veterinary 0.1 mg/kg comparator dose it requires only 0.025 ml/kg, so very small patients need a precise low-dead-space syringe; verify the exact insert, excipients, compatibility and single-use handling.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use systemic dexamethasone routinely for uncomplicated allergic reactions or anaphylaxis. Current RECOVER guidance recommends against routine glucocorticoids in both settings; treat anaphylaxis immediately with epinephrine and indicated resuscitation rather than delaying definitive therapy.
  • Avoid concurrent NSAIDs and allow an appropriate washout when switching. The combination materially increases gastrointestinal ulceration, perforation and bleeding risk; review aspirin, meloxicam, carprofen, firocoxib and every other anti-inflammatory exposure.
  • Do not suppress inflammation before excluding or actively treating relevant bacterial, fungal, viral or parasitic infection. Dexamethasone can mask progression, impair host defence and delay wound healing; avoid routine use in systemic infection or viraemia without a compelling, managed indication.
  • Avoid or undertake only an exceptional documented benefit-risk decision in diabetes mellitus, hyperadrenocorticism, gastrointestinal or corneal ulceration, glaucoma, osteoporosis, major cardiac or renal dysfunction and known corticosteroid/excipient hypersensitivity.
  • Do not use routinely during pregnancy: early exposure can cause fetal abnormalities and late exposure can precipitate abortion or premature parturition. Use in growing, lactating, geriatric or debilitated patients only after an individual benefit-risk assessment.
  • Do not combine with a live attenuated vaccine and avoid use around vaccination according to the applicable product information. Immunosuppression can reduce vaccine response; review other immunosuppressants and exposure to infectious disease.
  • Dexamethasone is long acting and suppresses the hypothalamic-pituitary-adrenal axis. Do not use alternate-day dexamethasone as an HPA-sparing strategy; after repeated or prolonged treatment taper rather than stop abruptly, and prefer a shorter-acting corticosteroid when long-term therapy is necessary.
  • Monitor thirst, urination, appetite, vomiting, diarrhoea or melaena, behaviour, body weight, blood pressure, glucose and electrolytes according to dose and duration. Review potassium-depleting diuretics, insulin needs, anticonvulsants and other medicines whose effect can change.
  • This is a 4 mg/ml human 1 ml ampoule, twice the concentration of the 2 mg/ml veterinary comparator. At 0.1 mg/kg, volume is 0.025 ml/kg: use a precise low-dead-space syringe, confirm IV versus IM intent and the exact insert/excipients, do not share a breached single-use ampoule and discard the remainder.
Assessment sources
  1. Dexamethasone ampoule market audit2026
  2. Dexamethasone 4 mg/mL human label2026
  3. VMD SPC 20252025
  4. VMD SPC 20252025
  5. RECOVER allergy/anaphylaxis2026
  6. AAHA allergic disease guideline2023
  7. MSD corticosteroids2026
  8. VetCompass glucocorticoid safety2020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care
6.1/10
Situational / acceptable
vetman assessment

Dexamethasone-AJIO

4 mg/ml, 1 ml ampoule, human medicine
Assessed clinical scopeCat · Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care · IV,IM
Care settingVeterinary clinic or hospital use after diagnosis and contraindication review, with exact small-volume measurement, route-specific administration, infection management and clinical/metabolic monitoring
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-038922 · Verified on 16 Oct 2026 Off-label use

A useful, precisely measurable clinic formulation when a diagnosed condition genuinely warrants parenteral dexamethasone and oral treatment is unsuitable. Its value is diagnosis-dependent, veterinary use of the exact human ampoule is off-label, and routine use for uncomplicated allergy or anaphylaxis is not supported; screen contraindications and avoid NSAID overlap.

Regulatory and scientific credibility5.5/10

The exact 4 mg/ml human ampoule has a sourced current Georgian registration and identifiable strength, route and manufacturer, but no current exact EU/EEA, GB or US registration was found. Animal use is off-label and formulation-specific veterinary evidence is absent.

Clinical efficacy6.0/10

Dexamethasone is a potent, established veterinary anti-inflammatory glucocorticoid and short systemic courses can be useful for selected severe inflammatory or immune-mediated disease. Benefit varies sharply by diagnosis: current RECOVER guidance recommends against routine glucocorticoids for uncomplicated allergy and anaphylaxis, and evidence does not validate every broad historical use or this exact human ampoule.

Safety and tolerability5.5/10

A single selected dose is usually tolerated, but dexamethasone is long acting and highly potent. It can worsen infection, hyperglycaemia, gastrointestinal ulceration, fluid/electrolyte disturbance, delayed healing and HPA suppression; pregnancy, diabetes, hyperadrenocorticism and major cardiac, renal, ocular or ulcer disease materially change the benefit-risk.

Clinical practicality8.0/10

The sterile 4 mg/ml, 1 ml ampoule supports rapid IV or IM clinic administration and avoids a prolonged home regimen. At the veterinary 0.1 mg/kg comparator dose it requires only 0.025 ml/kg, so very small patients need a precise low-dead-space syringe; verify the exact insert, excipients, compatibility and single-use handling.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use systemic dexamethasone routinely for uncomplicated allergic reactions or anaphylaxis. Current RECOVER guidance recommends against routine glucocorticoids in both settings; treat anaphylaxis immediately with epinephrine and indicated resuscitation rather than delaying definitive therapy.
  • Avoid concurrent NSAIDs and allow an appropriate washout when switching. The combination materially increases gastrointestinal ulceration, perforation and bleeding risk; review aspirin, meloxicam, carprofen, firocoxib and every other anti-inflammatory exposure.
  • Do not suppress inflammation before excluding or actively treating relevant bacterial, fungal, viral or parasitic infection. Dexamethasone can mask progression, impair host defence and delay wound healing; avoid routine use in systemic infection or viraemia without a compelling, managed indication.
  • Avoid or undertake only an exceptional documented benefit-risk decision in diabetes mellitus, hyperadrenocorticism, gastrointestinal or corneal ulceration, glaucoma, osteoporosis, major cardiac or renal dysfunction and known corticosteroid/excipient hypersensitivity.
  • Do not use routinely during pregnancy: early exposure can cause fetal abnormalities and late exposure can precipitate abortion or premature parturition. Use in growing, lactating, geriatric or debilitated patients only after an individual benefit-risk assessment.
  • Do not combine with a live attenuated vaccine and avoid use around vaccination according to the applicable product information. Immunosuppression can reduce vaccine response; review other immunosuppressants and exposure to infectious disease.
  • Dexamethasone is long acting and suppresses the hypothalamic-pituitary-adrenal axis. Do not use alternate-day dexamethasone as an HPA-sparing strategy; after repeated or prolonged treatment taper rather than stop abruptly, and prefer a shorter-acting corticosteroid when long-term therapy is necessary.
  • Monitor thirst, urination, appetite, vomiting, diarrhoea or melaena, behaviour, body weight, blood pressure, glucose and electrolytes according to dose and duration. Review potassium-depleting diuretics, insulin needs, anticonvulsants and other medicines whose effect can change.
  • This is a 4 mg/ml human 1 ml ampoule, twice the concentration of the 2 mg/ml veterinary comparator. At 0.1 mg/kg, volume is 0.025 ml/kg: use a precise low-dead-space syringe, confirm IV versus IM intent and the exact insert/excipients, do not share a breached single-use ampoule and discard the remainder.
Assessment sources
  1. Dexamethasone ampoule market audit2026
  2. Dexamethasone 4 mg/mL human label2026
  3. VMD SPC 20252025
  4. VMD SPC 20252025
  5. RECOVER allergy/anaphylaxis2026
  6. AAHA allergic disease guideline2023
  7. MSD corticosteroids2026
  8. VetCompass glucocorticoid safety2020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dexamethasone4 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular
Registration
Georgia Yes, human
In force until 24 Aug 2028
Human (Ministry of Health, RAMA)
In the register: დექსამეტაზონ-აჯიო 4 მგ/მლ, 1 მლ ამპულა
№ რ-038922
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Dexamethasone
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.05–0.2 mg/kg Dog Inflammation By mouth once daily in the morning
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.1 mg/kg Dog, Cat Allergic Reaction Intramuscular as needed
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexadreson 2 mg/ml Solution for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.05–0.2 mg/kg Cat Inflammation By mouth once daily in the evening
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical
    Do not use corticosteroids, topically or systemically, while a corneal ulcer is present. They slow healing of the corneal epithelium and can increase collagenase activity, which may turn the ulcer into a melting ulcer.
    Sources: MSD Vet Manual
  • Critical
    Do not use dexamethasone in animals with diabetes mellitus or hyperadrenocorticism unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with diabetes mellitus or hyperadrenocorticism.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with osteoporosis because corticosteroids increase protein catabolism and can reduce bone mass.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with cardiac or renal dysfunction, including congestive heart failure, unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    the product should not be used in animals suffering from diabetes, chronic nephritis, renal disease, congestive heart failure, osteoporosis and in viral infections during the viraemic stage
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with cardiac or renal dysfunction.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with gastro-intestinal ulceration.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with glaucoma.
    Sources: VMD SPC · VMD
  • Critical
    Do not use systemic dexamethasone in animals with burns unless specifically indicated and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone during pregnancy because early exposure can cause fetal abnormalities and late exposure can induce abortion or premature parturition.
    Sources: VMD SPC · VMD
  • Critical
    Known hypersensitivity to dexamethasone, another corticosteroid, or any excipient is a contraindication.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with viral or mycotic infections.
    Sources: VMD SPC · VMD
  • Warning
    Use with particular caution in an immunocompromised patient because corticosteroids delay wound healing and can exacerbate an existing infection.
    Sources: VMD SPC · VMD
  • Warning
    Corticoids such as dexamethasone should be used with caution in patients with hypertension.
    Sources: VMD SPC · VMD
  • Warning
    Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian.
    Sources: VMD SPC · VMD
  • Warning
    Do not use concomitantly with attenuated alive vaccine dexamethasone should not be used in combination with vaccines or within two weeks after vaccination
    Sources: VMD SPC · VMD
  • Caution
    Due to the long duration of effect of dexamethasone alternate day therapy is not an adequate way to allow the hypothalamic-pituitary-adrenal axis to recover.
    Sources: VMD SPC · VMD
  • Caution
    Use cautiously in geriatric or debilitated animals because corticosteroids increase protein catabolism. Prolonged treatment can cause cushingoid changes, including fat redistribution, muscle weakness and atrophy, and osteoporosis.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Contraindicated Robenacoxib + Dexamethasone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Meloxicam + Dexamethasone
    The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration.
    Recommendation: Avoid concurrent administration. Observe an appropriate washout period when switching. If both are essential, provide gastroprotection and monitor gastrointestinal signs closely.
    Sources: VMD SPC · VMD
  • Major warning Carprofen + Dexamethasone
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA
  • Major warning Dexamethasone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Dexamethasone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Minor warning Furosemide + Dexamethasone
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium. Hypokalaemia also increases cardiac glycoside toxicity.
    Sources: VMD SPC · VMD
  • Minor warning Dexamethasone + Torasemide
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (31 more) Hide additional products

Same active ingredients 9

Same therapeutic group 22

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗